[Dyslipidemia in the uremic patient: the therapeutic role played by simvastatin].
Simvastatin is a pharmacological molecule belonging to the family of HMG-CoA reductase inhibitors, recently included in plasma cholesterol lowering therapy. The authors carried out a study on the possible triglyceride lowering activity of simvastatin in dialyzed patients with chronic uremia considering its particular mechanism of action. The subjects selected for the study were suffering from uremia either complied with dosage prescribed or not. The obtained data showed the substance's triglyceride lowering effect, but no simvastatin-related side effect in the dialysed patients with uremia. For these reasons and for the substance's well-known cholesterol-lowering effect, simvastatin seems to deserve the definition of choice drug in the treatment of altered lipidemia in patients with uremia.